CLL Studies Presented at the 2016 Hematology Meeting Confirm Ibrutinib ’s Long-term Efficacy and Suggest Benefit From Second-line Agents

Discussion - Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure.

Source: Clinical Care Options Leukemia - January 6, 2017 Category: Hematology Source Type: research